BioPorto A/S in brief
BioPorto A/S is a listed company in the Diagnostics and Research industry, based in Denmark. It was founded in 1917. Its last known market value was $118 M (January 2024); there is no current figure. It employs about 15 people. Its shares trade under the symbol BIOPOR.CO (Copenhagen).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
BioPorto A/S timeline
- 1917
- 🏁· approximateFounded
- 2016
- •Legal Entity Identifier issuedLEI 5299004SWFL5JAN4W830 registered.
Events of BioPorto A/S from Wikidata and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Denmark: #84 (Jan 2020) · #73 (Jan 2021) · #84 (Jan 2022) · #74 (Dec 2022) · #93 (Jul 2023) · #75 (Jan 2024)
Balance sheet
- Total assets
- $16 M
- Total liabilities
- $4 M
- Total equity
- $12 M
As of June-2026
Mutual funds holding BioPorto A/S#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 World ex U.S. Core Equity PortfolioDimensional Fund Advisors LP | 51,729 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Dimensional International Small Cap ETFDimensional Fund Advisors LP | 21,781 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
As of Jul 31, 2026
BioPorto A/S: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in DKK millions; per-share figures in DKK; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 40 | 36 | 31 | 29 | 24 | 23 | |
| Cost of revenue | 9.9 | 12 | 11 | 9.9 | 9.2 | 9.9 | |
| Gross profit | 30 | 25 | 20 | 19 | 15 | 13 | |
| Research and development | 50 | 34 | 25 | 35 | 30 | 28 | |
| Selling and marketing | 27 | 30 | 19 | 21 | 17 | 21 | |
| General and administrative | 39 | 36 | 36 | 42 | 33 | 28 | |
| Operating income | −86 | −75 | −61 | −82 | −65 | −64 | |
| Interest and finance income | 0.5 | 2.5 | 1.0 | 1.2 | 2.5 | 0.0 | |
| Interest expense and finance costs | 2.1 | 0.8 | 1.1 | 1.2 | 1.0 | 3.2 | |
| Income before tax | −88 | −74 | −61 | −82 | −64 | −67 | |
| Income tax | −5.5 | −5.5 | −4.9 | −5.6 | −6.7 | −5.3 | |
| Net income including minority interests | −82 | −68 | −56 | −76 | −57 | −62 | |
| Earnings per share, basic | -0.18 | -0.17 | -0.16 | -0.24 | -0.21 | — | |
| Earnings per share, diluted | — | — | -0.16 | -0.24 | -0.21 | — | |
| Balance sheet | |||||||
| Cash and cash equivalents | 55 | 60 | 66 | 82 | 46 | 108 | |
| Receivables | 9.4 | 8.2 | 2.3 | 2.8 | 7.2 | 6.9 | |
| Inventory | 9.2 | 4.6 | 3.8 | 2.6 | 2.7 | 3.2 | |
| Current assets | 85 | 84 | 82 | 101 | 64 | 125 | |
| Property, plant and equipment | 1.5 | 2.1 | 0.9 | 1.6 | — | — | |
| Right-of-use (leased) assets | 4.8 | 6.6 | 1.3 | 2.9 | 12 | 10 | |
| Other intangible assets | 0.1 | 0.3 | 0.5 | 0.8 | 1.0 | 1.2 | |
| Non-current assets | 8.2 | 12 | 7.5 | 7.2 | 17 | 16 | |
| Total assets | 93 | 96 | 90 | 109 | 81 | 140 | |
| Current liabilities | 26 | 20 | 25 | 31 | 25 | 31 | |
| Lease liabilities (non-current) | 4.0 | 7.8 | 4.3 | 7.4 | 10 | 8.0 | |
| Non-current liabilities | 4.0 | 7.8 | 4.3 | 7.4 | 11 | 8.4 | |
| Total liabilities | 30 | 28 | 30 | 38 | 35 | 39 | |
| Retained earnings | −433 | −361 | −320 | −264 | −222 | −167 | |
| Total equity | 63 | 68 | 60 | 70 | 46 | 101 | |
| Total liabilities and equity | 93 | 96 | 90 | 109 | 81 | 140 | |
| Shares outstanding | — | — | — | 0.3 | 0.3 | — | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 2.5 | 2.4 | 2.7 | 4.0 | 4.3 | — | |
| Share-based compensation | −0.6 | −0.9 | 1.4 | 7.6 | −1.0 | 5.3 | |
| Cash from operating activities | −77 | −84 | −55 | −52 | −65 | −36 | |
| Capital expenditure | 0 | −0.4 | −0.0 | −0.4 | −0.1 | −1.3 | |
| Intangible assets bought | — | — | — | −0.1 | −0.3 | −0.2 | |
| Cash from investing activities | 1.3 | 1.2 | −0.3 | −0.5 | −0.4 | −1.5 | |
| Debt repaid | — | — | — | −0.3 | −0.2 | −0.2 | |
| Shares issued | 77 | — | — | — | — | 147 | |
| Cash from financing activities | 72 | 75 | 41 | 89 | 1.1 | 127 | |
| Exchange-rate effect on cash | −0.9 | 0.2 | −0.4 | 0.6 | 1.5 | −0.1 | |
| Report | ESEF | ESEF | ESEF | ESEF | ESEF | ESEF | |
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Dec 31, 2025
Peer comparison · Diagnostics and Research
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| BioPorto A/S🇩🇰 | $118 M | — | — | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
| Danaher Corporation🇺🇸 | $166.7 B | 38.5× | 16.9% | +2.9% |
| WuXi AppTec Co., Ltd.🇨🇳 | $70.4 B | 25.4× | 42.1% | — |
| Natera, Inc.🇺🇸 | $58.7 B | — | -5.7% | +35.9% |
| Siemens Healthineers AG🇩🇪 | $52.8 B | 22.9× | 8.7% | — |
| Lonza Group AG🇨🇭 | $51.9 B | — | -4.2% | — |
| Agilent Technologies, Inc.🇺🇸 | $48.8 B | 33.9× | 19.5% | +6.7% |
| IQVIA Holdings Inc.🇺🇸 | $45.1 B | 32.4× | 8.1% | +5.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Thermo Fisher Scientific Inc.$253.8 B
- Danaher Corporation$166.7 B
- WuXi AppTec Co., Ltd.$70.4 B
- Natera, Inc.$58.7 B
- Siemens Healthineers AG$52.8 B
- Lonza Group AG$51.9 B
How current the figures are
- Market cap:
- Jan 5, 2024 (last known)
- Balance sheet:
- As of June-2026
- Profile updated:
- Nov 15, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at BioPorto A/S? Verify and update this profile — free
Show BioPorto A/S's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.